Paper Details

  1. Home
  2. Paper Details

A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.

Author: AmeenVanessa, CarterEric G, GordonSusan H, HeathAmy T, KrauseRichard, PerschyTeresa, WestMarquita

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This randomized, double-blind, placebo-controlled study assessed the efficacy and tolerability of alosetron in treating chronic, severe diarrhea-predominant irritable bowel syndrome (d-IBS) in women. While alosetron was effective in managing d-IBS symptoms, constipation was the most common adverse event, highlighting the need for careful patient selection and monitoring.
Paper Details　
Original Abstract of the Article :
Alosetron is indicated for women with chronic, severe diarrhea-predominant IBS (d-IBS) who have not responded adequately to conventional therapy. Constipation is the most common adverse event with alosetron treatment. Multiple dosing regimens were assessed in a randomized, double-blind, placebo-cont...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1572-0241.2007.01282.x

データ提供：米国国立医学図書館（NLM）

Alosetron: A New Hope for Women with IBS-D

The world of [Gastrointestinal Research] is constantly evolving, and this research is a prime example. This study delves into the efficacy and safety of [Alosetron] for women with [severe diarrhea-predominant irritable bowel syndrome (d-IBS)]. The study employed a [randomized, double-blind, placebo-controlled] design to ensure reliable results. The researchers found that [Alosetron] was effective in treating d-IBS, but it’s important to note that [constipation] was a common side effect. This finding highlights the crucial need for careful monitoring and personalized treatment plans.

Alosetron: A Beacon of Hope for d-IBS, But with Caveats

The study's findings suggest that [Alosetron] could be a valuable tool in managing d-IBS, but the potential for [constipation] is a major concern. This reinforces the importance of a nuanced approach to treatment, carefully weighing the potential benefits against the risks. In a metaphorical sense, imagine [Alosetron] as a camel caravan traversing the vast desert of d-IBS. While the caravan brings relief and sustenance, it's crucial to be mindful of the potential obstacles along the way, such as [constipation], and prepare for them accordingly.

Alosetron: A Journey Through the Desert of d-IBS

The study's results offer hope for women struggling with d-IBS, but it's essential to consider the potential side effects. Like a wise traveler navigating a treacherous desert, it's important to be aware of the landscape and pack appropriately. By working closely with their healthcare providers, women with d-IBS can make informed decisions about their treatment plan and find a path to relief.

Dr. Camel's Conclusion

While [Alosetron] offers potential relief for women with d-IBS, it's important to be aware of the possible side effects and work closely with healthcare providers to make informed decisions about treatment.

Date :
  1. Date Completed 2007-09-14
  2. Date Revised 2022-03-18
Further Info :

Pubmed ID

17509028

DOI: Digital Object Identifier

10.1111/j.1572-0241.2007.01282.x

Related Literature

Article Analysis
・Effects of alosetron
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.